CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Adcetris for Hodgkin Lymphoma - Details

Project Number PC0020-000
Brand Name Adcetris
Generic Name Brentuximab vedotin
Strength 50 mg/vial
Tumour Type Lymphoma
Indication Hodgkin Lymphoma
Funding Request For HL patients after failure of ASCT or after failure of at least two prior therapies in patients who are not ASCT candidates
Review Status Complete
Pre Noc Submission No
NOC Date February 1, 2013
Manufacturer Seattle Genetics, Inc.
Sponsor Seattle Genetics, Inc.
Submission Date March 14, 2013
Submission Deemed Complete March 21, 2013
Submission Type Initial
Prioritization Requested Not Requested
Stakeholder Input Deadline ‡ March 28, 2013
Check-point meeting May 8, 2013
pERC Meeting June 20, 2013
Initial Recommendation Issued July 5, 2013
Feedback Deadline ‡ July 19, 2013
pERC Reconsideration Meeting August 15, 2013
Final Recommendation Issued August 29, 2013
Notification to Implement Issued September 16, 2013
Therapeutic Area Hodgkin Lymphoma
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.